Clinical Practice Recommendations on Genetic Testing of CYP2C9 and VKORC1 Variants in Warfarin Therapy

Objective: To systematically review evidence on genetic variants influencing outcomes during warfarin therapy and provide practice recommendations addressing the key questions: (1) Should genetic testing be performed in patients with an indication for warfarin therapy to improve achievement of stable anticoagulation and reduce adverse effects? (2) Are there subgroups of patients who may benefit more from genetic testing compared with others? (3) How should patients with an indication for warfarin therapy be managed based on their genetic test results? Methods: A systematic literature search was performed for VKORC1 and CYP2C9 and their association with warfarin therapy. Evidence was critically appraised, and clinical practice recommendations were developed based on expert group consensus. Results: Testing of VKORC1 (−1639G>A), CYP2C9*2, and CYP2C9*3 should be considered for all patients, including pediatric patients, within the first 2 weeks of therapy or after a bleeding event. Testing for CYP2C9*5, *6, *8, or *11 and CYP4F2 (V433M) is currently not recommended. Testing should also be considered for all patients who are at increased risk of bleeding complications, who consistently show out-of-range international normalized ratios, or suffer adverse events while receiving warfarin. Genotyping results should be interpreted using a pharmacogenetic dosing algorithm to estimate the required dose. Significance: This review provides the latest update on genetic markers for warfarin therapy, clinical practice recommendations as a basis for informed decision making regarding the use of genotype-guided dosing in patients with an indication for warfarin therapy, and identifies knowledge gaps to guide future research.

[1]  D. Roden,et al.  Clinical and Genetic Determinants of Warfarin Pharmacokinetics and Pharmacodynamics during Treatment Initiation , 2011, PloS one.

[2]  Y. Turpaz,et al.  CYP4F2 genetic variant alters required warfarin dose. , 2008, Blood.

[3]  Mark Crowther,et al.  Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). , 2008, Chest.

[4]  L. Kaminsky,et al.  Human P450 metabolism of warfarin. , 1997, Pharmacology & therapeutics.

[5]  D. Pollock,et al.  National surveillance of emergency department visits for outpatient adverse drug events. , 2006, JAMA.

[6]  L. Miao,et al.  Contribution of 1173C > T polymorphism in the VKORC1 gene to warfarin dose requirements in Han Chinese patients receiving anticoagulation. , 2011, International journal of clinical pharmacology and therapeutics.

[7]  C. Ki,et al.  Evaluation of the effects of VKORC1 polymorphisms and haplotypes, CYP2C9 genotypes, and clinical factors on warfarin response in Sudanese patients , 2011, European Journal of Clinical Pharmacology.

[8]  A. Thompson,et al.  Genetic and Clinical Determinants Influencing Warfarin Dosing in Children With Heart Disease , 2013, Pediatric Cardiology.

[9]  P. Ridker,et al.  Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism. , 2003, The New England journal of medicine.

[10]  M. Pirmohamed,et al.  A Proposal for an Individualized Pharmacogenetics‐Based Warfarin Initiation Dose Regimen for Patients Commencing Anticoagulation Therapy , 2011, Clinical pharmacology and therapeutics.

[11]  M. Rieder,et al.  Use of Pharmacogenetic and Clinical Factors to Predict the Therapeutic Dose of Warfarin , 2008, Clinical pharmacology and therapeutics.

[12]  N. Limdi,et al.  Influence of CYP2C9 and VKORC1 on warfarin response during initiation of therapy. , 2009, Blood cells, molecules & diseases.

[13]  S. Hutson,et al.  Warfarin and the Vitamin K-Dependent γ-Carboxylation System , 2004 .

[14]  M. Hayden,et al.  VKORC1 and CYP2C9 genotypes are predictors of warfarin‐related outcomes in children , 2014, Pediatric blood & cancer.

[15]  Deborah A Nickerson,et al.  Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. , 2005, The New England journal of medicine.

[16]  Michelle E. Kho,et al.  AGREE II: advancing guideline development, reporting and evaluation in health care , 2010, Canadian Medical Association Journal.

[17]  Eun-Young Kim,et al.  Effect of CYP2C9 and VKORC1 genotypes on early-phase and steady-state warfarin dosing in Korean patients with mechanical heart valve replacement , 2009, Pharmacogenetics and genomics.

[18]  W. Zhang,et al.  Genetic polymorphisms are associated with variations in warfarin maintenance dose in Han Chinese patients with venous thromboembolism. , 2012, Pharmacogenomics.

[19]  M. Shearer,et al.  Pharmacodynamic resistance to warfarin associated with a Val66Met substitution in vitamin K epoxide reductase complex subunit 1 , 2004, Thrombosis and Haemostasis.

[20]  M. Ratain,et al.  Meaningful Use of Pharmacogenetics , 2014, Clinical pharmacology and therapeutics.

[21]  Jean-Louis Golmard,et al.  Vitamin K antagonists in children with heart disease: height and VKORC1 genotype are the main determinants of the warfarin dose requirement. , 2012, Blood.

[22]  J. Hirsh,et al.  Managing oral anticoagulant therapy. , 2001, Chest.

[23]  U. Amstutz,et al.  Recommendations for HLA‐B*15:02 and HLA‐A*31:01 genetic testing to reduce the risk of carbamazepine‐induced hypersensitivity reactions , 2014, Epilepsia.

[24]  Shiew-Mei Huang,et al.  A Regulatory Science Perspective on Warfarin Therapy: A Pharmacogenetic Opportunity , 2009, Journal of clinical pharmacology.

[25]  Russ B. Altman,et al.  Extending and evaluating a warfarin dosing algorithm that includes CYP4F2 and pooled rare variants of CYP2C9 , 2010, Pharmacogenetics and genomics.

[26]  Munir Pirmohamed,et al.  A Randomized Trial of Genotype-Guided Dosing of Warfarin , 2014 .

[27]  Margaret C Fang,et al.  Advanced Age, Anticoagulation Intensity, and Risk for Intracranial Hemorrhage among Patients Taking Warfarin for Atrial Fibrillation , 2004, Annals of Internal Medicine.

[28]  C. Eby.  The Pharmacogenetics of Vitamin K Antagonist Anticoagulation Drugs , 2011 .

[29]  A. Mrhar,et al.  Influence of CYP2C9 polymorphisms, demographic factors and concomitant drug therapy on warfarin metabolism and maintenance dose , 2005, The Pharmacogenomics Journal.

[30]  Michael Sobel,et al.  Anticoagulants: to bleed or not to bleed, that is the question. , 2002, Seminars in vascular surgery.

[31]  G. Suarez-Kurtz,et al.  Impact of CYP4F2 rs2108622 on the Stable Warfarin Dose in an Admixed Patient Cohort , 2010, Clinical pharmacology and therapeutics.

[32]  H. Uyarel,et al.  The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements in an adult Turkish population , 2010, Heart and Vessels.

[33]  M. Ritchie,et al.  Different contributions of polymorphisms in VKORC1 and CYP2C9 to intra- and inter-population differences in maintenance dose of warfarin in Japanese, Caucasians and African-Americans , 2006, Pharmacogenetics and genomics.

[34]  H. Halkin,et al.  Vitamin K Intake and Sensitivity to Warfarin in Patients Consuming Regular Diets , 1999, Thrombosis and Haemostasis.

[35]  R. Altman,et al.  Estimation of the warfarin dose with clinical and pharmacogenetic data. , 2009, The New England journal of medicine.

[36]  C. Thorn,et al.  Warfarin Response and Vitamin K Epoxide Reductase Complex 1 in African Americans and Caucasians , 2007, Clinical pharmacology and therapeutics.

[37]  C. Hızel,et al.  Impact of Genetic Factors (CYP2C9, VKORC1 and CYP4F2) on Warfarin Dose Requirement in the Turkish Population , 2013, Basic & clinical pharmacology & toxicology.

[38]  A. Mehdipour,et al.  The impact of genetic polymorphisms and patient characteristics on warfarin dose requirements: a cross-sectional study in Iran. , 2010, Clinical therapeutics.

[39]  Edith Nutescu,et al.  Pharmacogenomics of warfarin dose requirements in Hispanics. , 2011, Blood cells, molecules & diseases.

[40]  T. Langaee,et al.  Genetic and Clinical Predictors of Warfarin Dose Requirements in African Americans , 2010, Clinical pharmacology and therapeutics.

[41]  M. Margaglione,et al.  A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin. , 2005, Blood.

[42]  Andreas Fregin,et al.  Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2 , 2004, Nature.

[43]  D. Wysowski,et al.  Bleeding complications with warfarin use: a prevalent adverse effect resulting in regulatory action. , 2007, Archives of internal medicine.

[44]  H. Halkin,et al.  A coding VKORC1 Asp36Tyr polymorphism predisposes to warfarin resistance. , 2007, Blood.

[45]  R. Califf,et al.  A pharmacogenetic versus a clinical algorithm for warfarin dosing. , 2013, The New England journal of medicine.

[46]  A. Jonzon,et al.  Warfarin dose prediction in children using pharmacometric bridging—comparison with published pharmacogenetic dosing algorithms , 2013, European Journal of Clinical Pharmacology.

[47]  R. Beyth,et al.  Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin. , 1998, The American journal of medicine.

[48]  A. Sajantila,et al.  Pharmacogenetic variation at CYP2C9, CYP2C19, and CYP2D6 at global and microgeographic scales , 2009, Pharmacogenetics and genomics.

[49]  Elena Deych,et al.  Gamma-glutamyl carboxylase and its influence on warfarin dose , 2010, Thrombosis and Haemostasis.

[50]  S. Hutson,et al.  Warfarin and the vitamin K-dependent gamma-carboxylation system. , 2004, Trends in molecular medicine.

[51]  M. Gibaldi,et al.  The mechanism of the interaction between amiodarone and warfarin in humans , 1992, Clinical pharmacology and therapeutics.

[52]  J. Turgeon,et al.  Combination of Phenotype Assessments and CYP2C9‐VKORC1 Polymorphisms in the Determination of Warfarin Dose Requirements in Heavily Medicated Patients , 2008, Clinical pharmacology and therapeutics.

[53]  G. Ayers,et al.  The impact of age and CYP2C9 and VKORC1 variants on stable warfarin dose in the paediatric population , 2014, British journal of haematology.

[54]  Nicole Soranzo,et al.  A Genome-Wide Association Study Confirms VKORC1, CYP2C9, and CYP4F2 as Principal Genetic Determinants of Warfarin Dose , 2009, PLoS genetics.

[55]  Peter Wood,et al.  The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. , 2005, Blood.

[56]  J. Goldstein,et al.  Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data. , 2002, Pharmacogenetics.

[57]  E. Hylek,et al.  Risk Factors for Intracranial Hemorrhage in Outpatients Taking Warfarin , 1994, Annals of Internal Medicine.

[58]  Dan M Roden,et al.  Genetic determinants of response to warfarin during initial anticoagulation. , 2008, The New England journal of medicine.

[59]  R. Kim,et al.  Genotype-guided dosing of vitamin K antagonists. , 2014, The New England journal of medicine.

[60]  F. Kamali,et al.  Characterizing variability in warfarin dose requirements in children using modelling and simulation , 2013, British journal of clinical pharmacology.

[61]  J. Halperin,et al.  CYP2C9*8 is prevalent among African-Americans: implications for pharmacogenetic dosing. , 2009, Pharmacogenomics.

[62]  P. Wells,et al.  The outpatient bleeding risk index: validation of a tool for predicting bleeding rates in patients treated for deep venous thrombosis and pulmonary embolism. , 2003, Archives of internal medicine.

[63]  R. Altman,et al.  Pharmacogenomics: “Noninferiority” Is Sufficient for Initial Implementation , 2011, Clinical pharmacology and therapeutics.

[64]  B. Chowbay,et al.  Influence of CYP4F2 rs2108622 (V433M) on warfarin dose requirement in Asian patients. , 2011, Drug metabolism and pharmacokinetics.

[65]  Felix W Frueh,et al.  Back to the future: why randomized controlled trials cannot be the answer to pharmacogenomics and personalized medicine. , 2009, Pharmacogenomics.

[66]  F. Kamali,et al.  Warfarin dose prediction in children using pharmacogenetics information , 2012, British journal of haematology.

[67]  D. Nicolae,et al.  The Missing Association: Sequencing‐Based Discovery of Novel SNPs in VKORC1 and CYP2C9 That Affect Warfarin Dose in African Americans , 2011, Clinical pharmacology and therapeutics.

[68]  D. Hu,et al.  Impact of CYP2C9*3, VKORC1-1639, CYP4F2rs2108622 genetic polymorphism and clinical factors on warfarin maintenance dose in Han-Chinese patients , 2012, Journal of Thrombosis and Thrombolysis.

[69]  Stephen E Kimmel,et al.  Genetic warfarin dosing: tables versus algorithms. , 2011, Journal of the American College of Cardiology.

[70]  D. Roden,et al.  Prospective evaluation of a pharmacogenetics-guided warfarin loading and maintenance dose regimen for initiation of therapy. , 2011, Blood.

[71]  F. Kamali,et al.  VKORC1 and CYP2C9 genotype and patient characteristics explain a large proportion of the variability in warfarin dose requirement among children. , 2012, Blood.

[72]  R. Kittles,et al.  Genotype-guided dosing of vitamin K antagonists. , 2014, The New England journal of medicine.

[73]  Dan M. Bolser,et al.  Ensembl Genomes 2013: scaling up access to genome-wide data , 2013, Nucleic Acids Res..

[74]  J. Lewis,et al.  Pharmacogenetic Impact of VKORC1 and CYP2C9 Allelic Variants on Warfarin Dose Requirements in a Hispanic Population Isolate , 2010, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

[75]  Arnaud Perrier,et al.  Clinical impact of bleeding in patients taking oral anticoagulant therapy for venous thromboembolism: a meta-analysis, L.A. Linkins, P.T. Choi, J.D. Douketis, in: Ann Intern Med, 139. (2003), 893 , 2004 .

[76]  Valentin Fuster,et al.  American Heart Association/American College of Cardiology Foundation guide to warfarin therapy. , 2003, Circulation.